Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion

Pierre Fenaux; David Bowen; Norbert Gattermann; Eva Hellström-Lindberg; Wolf-Karsten Hofmann; Michael Pfeilstöcker; Guillermo Sanz; Valeria Santini

doi:10.1016/j.leukres.2010.05.021

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion

Leuk Res. 2010 Nov;34(11):1410-6. doi: 10.1016/j.leukres.2010.05.021. Epub 2010 Jul 6.

Authors

Pierre Fenaux¹, David Bowen, Norbert Gattermann, Eva Hellström-Lindberg, Wolf-Karsten Hofmann, Michael Pfeilstöcker, Guillermo Sanz, Valeria Santini

Affiliation

¹ Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France. pierre.fenaux@avc.aphp.fr

PMID: 20609474
DOI: 10.1016/j.leukres.2010.05.021

Abstract

Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antimetabolites, Antineoplastic
Azacitidine / therapeutic use*
Expert Testimony*
Humans
Myelodysplastic Syndromes / drug therapy*
Risk

Substances

Antimetabolites, Antineoplastic
Azacitidine